Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?  

作　　者：Giorgia Marisi Alessandro Cucchetti Paola Ulivi Matteo Canale Giuseppe Cabibbo Leonardo Solaini Francesco G Foschi Serena De Matteis Giorgio Ercolani Martina Valgiusti Giovanni L Frassineti Mario Scartozzi Andrea Casadei Gardini 

机构地区：[1]Biosciences Laboratory,Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS [2]Department of Medical and Surgical Sciences,Alma Mater Studiorum,University of Bologna [3]General and Oncologic Surgery,Morgagni-Pierantoni Hospital [4]Section of Gastroenterology,DI.BI.M.I.S.,University of Palermo [5]Department of Internal Medicine,Degli Infermi Hospital [6]Department of Medical Oncology,Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRCCS [7]Department of Medical Oncology,University of Cagliari

出　　处：《World Journal of Gastroenterology》2018年第36期4152-4163,共12页世界胃肠病学杂志（英文版）

摘　　要：Sorafenib has been considered the standard of care for patients with advanced unresectable hepatocellular carcinoma(HCC) since 2007 and numerous studieshave investigated the role of markers involved in the angiogenesis process at both the expression and genetic level and clinical aspect. What results have ten years of research produced? Several clinical and biological markers are associated with prognosis. The most interesting clinical parameters are adverse events, Barcelona Clinic Liver Cancer stage, and macroscopic vascular invasion, while several single nucleotide polymorphisms and plasma angiopoietin-2 levels represent the most promising biological biomarkers. A recent pooled analysis of two phase III randomized trials showed that the neutrophil-to-lymphocyte ratio, etiology and extra-hepatic spread are predictive factors of response to sorafenib, but did not identify any predictive biological markers. After 10 years of research into sorafenib there are still no validated prognostic or predictive factors of response to the drug in HCC. The aim of the present review was to summarize 10 years of research into sorafenib, looking in particular at the potential of associated clinical and biological markers to predict its efficacy in patients with advanced HCC.Sorafenib has been considered the standard of care for patients with advanced unresectable hepatocellular carcinoma(HCC) since 2007 and numerous studieshave investigated the role of markers involved in the angiogenesis process at both the expression and genetic level and clinical aspect. What results have ten years of research produced? Several clinical and biological markers are associated with prognosis. The most interesting clinical parameters are adverse events, Barcelona Clinic Liver Cancer stage, and macroscopic vascular invasion, while several single nucleotide polymorphisms and plasma angiopoietin-2 levels represent the most promising biological biomarkers. A recent pooled analysis of two phase III randomized trials showed that the neutrophil-to-lymphocyte ratio, etiology and extra-hepatic spread are predictive factors of response to sorafenib, but did not identify any predictive biological markers. After 10 years of research into sorafenib there are still no validated prognostic or predictive factors of response to the drug in HCC. The aim of the present review was to summarize 10 years of research into sorafenib, looking in particular at the potential of associated clinical and biological markers to predict its efficacy in patients with advanced HCC.

关 键 词：Biomarker ANGIOPOIETIN Neutrophil-tolymphocyte ratio POLYMORPHISMS SORAFENIB MicroRNA ADVERSE events Hepatocellular carcinoma Vascular ENDOTHELIAL growth factor 

分 类 号：R57[医药卫生—消化系统]